Arrowhead Research ARWR Debt-to-equity

Debt-to-equity at other companies

Ionis PharmaceuticalsIONS

0.6×-0.7×

ALN

Alnylam PharmaceuticalsALNY

0.2×-0.9×

Assembly BiosciencesASMB

0×-0.1×

Arbutus Biopharma CorporationABUS

0×0.0×

Ultragenyx PharmaceuticalRARE

3.7×—

Beam TherapeuticsBEAM

0.2×+0.1×

FAQ

What is Arrowhead Research's debt-to-equity?

Arrowhead Research (ARWR) reported debt-to-equity of 0.2× in Q1 2026.

How has Arrowhead Research's debt-to-equity changed year-over-year?

Arrowhead Research's debt-to-equity increased by 5.0% year-over-year, from 0.2× to 0.2×.

What is the long-term trend for Arrowhead Research's debt-to-equity?

Over 4 years (2021 to 2025), Arrowhead Research's debt-to-equity has grown at a 39.8% compound annual growth rate (CAGR), from 0.1× to 0.2×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.